Research monograph · epo helix-b surface derived 11-amino-acid peptide
Inflammation & Neuroprotection Studies
This monograph collects what the published literature reports about ARA-290 — its mechanisms, the areas it is studied in, its molecular record and the sources behind them. That region is the part of the hormone that engages tissue-protective signaling, and isolating it separates that activity from erythropoietin's effect on red blood cell production. Research interest centers on inflammatory signaling and small-fibre nerve endpoints.
For laboratory research use only — not for human or animal use
Mechanisms
IRR (EPOR/CD131) Agonism
The eleven residues are taken from the helix-B surface of erythropoietin, the region that engages the innate repair receptor. Isolating it selects for tissue-protective signalling and leaves behind the receptor interaction that drives red cell production.
Resolution of Inflammation
Signalling through the innate repair receptor is described as dampening pro-inflammatory activity and actively promoting its resolution, rather than simply suppressing the response.
Cytoprotective & Neuroregenerative Signaling
Receptor activation is reported to engage JAK2/STAT3, PI3K/Akt and anti-apoptotic Bcl-2-family signalling. Small-fibre nerve endpoints are where that cytoprotective activity has been measured most often.
Studied applications
Small-fibre neuropathy in sarcoidosis is the indication with the most developed clinical record for this peptide.
Heij et al. 2012
Corneal confocal microscopy and skin biopsy allow nerve fibre density to be counted directly, which makes these unusually concrete endpoints.
Dahan et al. 2013
Preclinical pain models measure allodynia persistence after dosing stops — a design that tests for durable change rather than symptomatic cover.
Swartjes et al. 2014
The tissue-protective signalling is inherited from erythropoietin, minus the effect on red cell production that the parent hormone carries.
Brines et al. 2008
What the published work measures
The endpoints reported across the literature for this compound. The figures belong to the individual papers, not to us.
Reference values
Scroll for full molecular data →
| Sequence | pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser (11 aa) |
|---|---|
| Molecular weight | 1,257.30 g/mol |
| Molecular formula | C₅₁H₈₄N₁₆O₂₁ |
| Physical form | Lyophilized powder |
| Documented purity | Quantified by HPLC, reported per lot |
| Storage | -20°C for long-term stability |
| Solubility | Sterile or bacteriostatic water |
| Available sizes | 10mg |
FAQ
ARA-290, also called cibinetide, is an 11-residue sequence lifted from a single region of erythropoietin. That region is the part of the hormone that engages tissue-protective signaling, and isolating it separates that activity from erythropoietin's effect on red blood cell production. Research interest centers on inflammatory signaling and small-fibre nerve endpoints.
Published research on ARA-290 concentrates on Sarcoidosis Small-Fiber Neuropathy, Corneal & Skin Nerve Fiber Regrowth, Long-Term Allodynia Relief and EPO-Derived Cytoprotection. Each of those areas is summarised further up this page with the citation it comes from, and the full reference list — 4 indexed publications — sits at the bottom. Study designs and concentrations vary considerably between publications, so the primary sources are worth reading directly.
The literature describes ARA-290 acting across IRR (EPOR/CD131) Agonism, Resolution of Inflammation and Cytoprotective & Neuroregenerative Signaling, reported respectively as Innate Repair Receptor, Anti-Inflammatory and Tissue Protection. Those pathways are drawn from preclinical models rather than clinical work, and they describe what has been observed rather than a settled mechanism — the individual pathway cards above cite what each one is based on.
ARA-290 has a molecular formula of C51H84N16O21, an average mass of 1257.3 g/mol and the sequence pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser (11 aa). It is indexed under CAS 1208243-50-8. It ships as lyophilized powder. Those are nominal reference values for the parent compound. The identity of the specific material you receive is confirmed by mass spectrometry and reported on that lot's certificate.
Store the sealed vial at -20°C, protected from light and moisture, and let it reach room temperature before opening so condensation does not form on cold powder. ARA-290 is sterile or bacteriostatic water; reconstitute by directing the diluent down the vial wall rather than onto the powder, then swirl to dissolve rather than shaking. Keep reconstituted solution refrigerated and avoid repeated freeze-thaw cycles — solutions are far less stable than lyophilized powder.
No. ARA-290 is supplied strictly for in-vitro laboratory research and development. It is not a drug, food, supplement or cosmetic, it has not been evaluated by the FDA, and it is not intended for human or animal consumption, ingestion, injection or any in-vivo use. Ordering confirms you are a qualified researcher or institution purchasing on that basis.
Cited sources
Independent published research indexed from PubMed — not Routine Peptides claims.
Before you order
Every production run is analyzed by an independent laboratory, and the certificate for your lot travels with the order — not a catalog-wide document, and not a summary written by us.
